scholarly journals Chemical Reporter for Visualizing Metabolic Cross-Talk between Carbohydrate Metabolism and Protein Modification

2014 ◽  
Vol 9 (9) ◽  
pp. 1991-1996 ◽  
Author(s):  
Balyn W. Zaro ◽  
Kelly N. Chuh ◽  
Matthew R. Pratt
Keyword(s):  
Carbohydrate Metabolism ◽  
Cross Talk ◽  
Protein Modification ◽  
Chemical Reporter

scholarly journals The Metabolic Chemical Reporter Ac46AzGal Could Incorporate Intracellular Protein Modification in the Form of UDP-6AzGlc Mediated by OGT and Enzymes in the Leloir Pathway

2021 ◽  
Vol 9 ◽  
Author(s):  
Jiajia Wang ◽  
Biao Dou ◽  
Lu Zheng ◽  
Wei Cao ◽  
Peiyu Dong ◽  
...  
Keyword(s):  
Mammalian Cells ◽  
Protein Modification ◽  
Time Dependent ◽  
Dependent Manner ◽  
Intracellular Protein ◽  
Galactose Metabolism ◽  
Naturally Occurring ◽  
Leloir Pathway ◽  
Chemical Reporter ◽  
Complex Glycans

Galactose is a naturally occurring monosaccharide used to build complex glycans that has not been targeted for labeling as a metabolic reporter. Here, we characterize the cellular modification of proteins by using Ac46AzGal in a dose- and time-dependent manner. It is noted that a vast majority of this labeling of Ac46AzGal occurs intracellularly in a range of mammalian cells. We also provided evidence that this labeling is dependent on not only the enzymes of OGT responsible for O-GlcNAcylation but also the enzymes of GALT and GALE in the Leloir pathway. Notably, we discover that Ac46AzGal is not the direct substrate of OGT, and the labeling results may attribute to UDP-6AzGlc after epimerization of UDP-6AzGal via GALE. Together, these discoveries support the conclusion that Ac46AzGal as an analogue of galactose could metabolically label intracellular O-glycosylation modification, raising the possibility of characterization with impaired functions of the galactose metabolism in the Leloir pathway under certain conditions, such as galactosemias.

scholarly journals Correction to “An Alkyne–Aspirin Chemical Reporter for the Detection of Aspirin-Dependent Protein Modification in Living Cells”

2018 ◽  
Vol 140 (14) ◽  
pp. 4954-4954
Author(s):  
Leslie A. Bateman ◽  
Balyn W. Zaro ◽  
Stephanie M. Miller ◽  
Matthew R. Pratt
Keyword(s):  
Protein Modification ◽  
Living Cells ◽  
Chemical Reporter ◽  
Dependent Protein

scholarly journals Quantification of exercise‐regulated ubiquitin signaling in human skeletal muscle identifies protein modification cross talk via NEDDylation

2020 ◽  
Vol 34 (4) ◽  
pp. 5906-5916 ◽  
Author(s):  
Benjamin L. Parker ◽  
Bente Kiens ◽  
Jørgen F. P. Wojtaszewski ◽  
Erik A. Richter ◽  
David E. James
Keyword(s):  
Skeletal Muscle ◽  
Cross Talk ◽  
Protein Modification ◽  
Human Skeletal Muscle

Cross-talk unfolded: MARCKS proteins

2002 ◽  
Vol 362 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Anna ARBUZOVA ◽  
Arndt A. P. SCHMITZ ◽  
Guy VERGÈRES
Keyword(s):  
Actin Cytoskeleton ◽  
Cross Talk ◽  
Protein Modification ◽  
Membrane Binding ◽  
Point Of View ◽  
Cellular Migration ◽  
Effector Domain ◽  
Kinase Substrate ◽  
Natively Unfolded

The proteins of the MARCKS (myristoylated alanine-rich C kinase substrate) family were first identified as prominent substrates of protein kinase C (PKC). Since then, these proteins have been implicated in the regulation of brain development and postnatal survival, cellular migration and adhesion, as well as endo-, exo- and phago-cytosis, and neurosecretion. The effector domain of MARCKS proteins is phosphorylated by PKC, binds to calmodulin and contributes to membrane binding. This multitude of mutually exclusive interactions allows cross-talk between the signal transduction pathways involving PKC and calmodulin. This review focuses on recent, mostly biophysical and biochemical results renewing interest in this protein family. MARCKS membrane binding is now understood at the molecular level. From a structural point of view, there is a consensus emerging that MARCKS proteins are ‘natively unfolded'. Interestingly, domains similar to the effector domain have been discovered in other proteins. Furthermore, since the effector domain enhances the polymerization of actin in vitro, MARCKS proteins have been proposed to mediate regulation of the actin cytoskeleton. However, the recent observations that MARCKS might serve to sequester phosphatidylinositol 4,5-bisphosphate in the plasma membrane of unstimulated cells suggest an alternative model for the control of the actin cytoskeleton. While myristoylation is classically considered to be a co-translational, irreversible event, new reports on MARCKS proteins suggest a more dynamic picture of this protein modification. Finally, studies with mice lacking MARCKS proteins have investigated the functions of these proteins during embryonic development in the intact organism.

An Alkyne–Aspirin Chemical Reporter for the Detection of Aspirin-Dependent Protein Modification in Living Cells

2013 ◽  
Vol 135 (39) ◽  
pp. 14568-14573 ◽  
Author(s):  
Leslie A. Bateman ◽  
Balyn W. Zaro ◽  
Stephanie M. Miller ◽  
Matthew R. Pratt
Keyword(s):  
Protein Modification ◽  
Living Cells ◽  
Chemical Reporter ◽  
Dependent Protein

„Cross-talk“ zwischen Herz und Niere – das Kardiorenale Syndrom und seine Therapie aus der Sicht des Nephrologen

2009 ◽  
Vol 66 (11) ◽  
pp. 741-746 ◽  
Author(s):  
Stefan Farese
Keyword(s):  
Cross Talk

Herz und Nierenfunktion sind eng miteinander verknüpft. Ein Großteil der Patienten mit chronischer Herzinsuffizienz leidet gleichzeitig an einer Nierenfunktionsstörung. Diese ist kausal an der Entwicklung der Herzinsuffizienz beteiligt und stellt damit einen wichtigen prognostischen Faktor dar. Pathophysiologisch kommt es durch die verminderte renale Perfusion zu einer Aktivierung verschiedener Regelkreise, die eine Salz- und Wasserretention induzieren und damit das Fortschreiten der Herzinsuffizienz begünstigen. Therapeutische Ziele sind die Euvolämie sowie die kontrollierte Behandlung mittels prognostisch relevanter, kardialer Begleitmedikation. Können diese beiden Ziele aufgrund von Therapieresistenz, progredienter Niereninsuffizienz oder Therapie-Nebenwirkungen nicht erreicht werden, ist die Indikation für ein Nierenersatzverfahren gegeben. Prinzipiell können alle heute verfügbaren Verfahren angewendet werden. Die Auswahl der Modalität sollte jedoch an die individuelle Situation des Patienten angepasst und interdisziplinär besprochen werden. Obwohl sich unter Therapie bei allen Nierenersatzverfahren funktionelle und subjektive Verbesserungen nachweisen lassen, ist deren Einfluss auf die Langzeitprognose ungeklärt.

Sign in / Sign up

Export Citation Format

Share Document